Pending sale of Coflex/CoFix and international hardware business
The transactions may be delayed, fail to close, or distract management and disrupt customers and suppliers.
- Scope
- Core business relationships and operating continuity
- Materiality
- high
Xtant Medical Holdings, Inc.
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons. Its portfolio includes orthobiologics for bone healing as well as spinal implants and instrumentation, sold primarily in the United States and also through international distribution channels.
9,3 %
62,9 %
3,7 %
+14,2 %
2.65
1.63
| % | |
|---|---|
| Orthobiologics | 55% Biologic products used to support bone growth and healing in spine and orthopedic procedures. |
| Spine hardware and instrumentation | 35% Implants, fixation systems, and surgical instrumentation used in spinal disease treatment. |
| Allografts and regenerative tissue products | 10% Human tissue-based products including bone matrices and amniotic membrane allografts. |
Xtant sells to orthopedic and neurological surgeons through independent distributors, stocking agents, and direct...
- Orthopedic surgeonsprimary
Buy orthobiologics and graft products to support bone healing in surgical procedures.
- Neurological and spine surgeonsprimary
Buy spinal implants, fixation systems, and instrumentation for spine surgery.
- Independent distributors and stocking agentsprimary
Purchase and place products into accounts, helping drive surgeon adoption and hospital access.
- IDNs and GPOssecondary
Provide purchasing access and contracting leverage for hospitals and surgical networks.
- International stocking partnerssecondary
Distribute products in Europe, Canada, Mexico, South America, Australia, and Pacific markets.
The company is centered on the United States, where it sells through independent agents, stocking distributors, and...
- •United States is the core commercial market
- •Sales access includes IDNs and GPOs across the U.S.
- •International sales run through direct reps and stocking partners
- •Europe, Canada, Mexico, South America, Australia, and Pacific regions are served
- •Geographic breadth supports growth but increases regulatory and channel complexity
Xtant is focused on expanding its product portfolio, broadening distribution, and entering adjacent markets around...
01
New product introductionsshort-term
Fresh products help defend surgeon relationships and expand use cases in spine and orthobiologics.
02
Distribution expansionshort-term
A broader channel footprint improves access to hospitals, surgeons, and regional accounts.
03
Adjacent market penetrationmedium-term
Moving into related surgical categories can increase wallet share with existing customers.
04
Strategic transactions and acquisitionsmedium-term
Deals can add products, technology, or distribution reach without building everything internally.
Xtant faces execution risk from product launches, channel dependence, and the complexity of selling through...
Need for additional financing
The company may require capital before expected cash resources are exhausted, and terms may be unfavorable.
- Scope
- Liquidity and strategic flexibility
- Materiality
- high
Channel concentration and distributor dependence
Sales rely heavily on independent agents and stocking distributors, which can affect coverage and pricing control.
- Scope
- U.S. commercial execution
- Materiality
- high
Product adoption and launch risk
New biologics and spine systems must gain surgeon acceptance and hospital access to scale.
- Scope
- Trivium, Cortera, SimpliGraft, SimpliMax
- Materiality
- medium
Regulatory and reimbursement pressure
Medical device and biologics businesses depend on approvals, compliance, and payer acceptance.
- Scope
- Spine and regenerative medicine markets
- Materiality
- high
Revenue recognition
Affects quarterly revenue timing and comparability
Transaction accounting
Can materially affect reported operating results
Debt and interest expense
Affects net income and liquidity analysis
Impairment and valuation
Could create non-cash charges to earnings
: 29.4.2026